DES restenosis rates on the rise?
This article was originally published in The Gray Sheet
Executive Summary
"As sirolimus-coated stents move into general use, it is likely that the rate of restenosis will be higher than that shown in the SIRIUS trial," Andrew Marks, MD, states in Oct. 2 New England Journal of Medicine editorial. The article accompanies publication of the Johnson & Johnson/Cordis Cypher sirolimus-eluting stent study, in which the device was associated with an 8.9% six-month binary restenosis rate. Marks cites a 121-patient series by Pero Lemos, MD, Erasmus Medical Center, Rotterdam, showing 16% restenosis (1"The Gray Sheet" Sept. 22, 2003, p. 4)...